Drug intelligence / Profile preview

ACM-011

Development stage: Preclinical
Lead developer: ACM Biolabs
Modality: Small Molecules

Overview

ACM-011 is a novel investigational drug developed by ACM Biolabs. It acts as an agonist of toll-like receptor 7 (TLR7) and toll-like receptor 8 (TLR8), both of which are key components in the innate immune system. By activating these receptors, ACM-011 is designed to stimulate immune responses that may be beneficial in the treatment of cancer. The drug is classified as an antineoplastic agent and represents a new molecular entity. As of the latest updates, its development status remains at the preclinical stage for cancer indications[1][2][5].

Targets

TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on ACM-011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACM-011.

Explore the full profile